Avanos Medical, Inc. — Cyborg Score 6/10

Solid
Medical Devices & Equipment Manufacturing

Strategic Profile

Avanos differentiates itself through its portfolio of leading pain management products (ON-Q, Game Ready, COOLIEF) and chronic care solutions (Mic-Key, Corpak, NeoMed), capturing growth opportunities in the high-demand opioid-reduction and specialized nutrition markets. The company's market position is reinforced by direct relationships with hospitals and healthcare providers, complemented by ongoing R&D investment to maintain competitive advantage.

Cyborg Score Rationale

Avanos operates in attractive, high-growth healthcare markets with strong regulatory moats and established market positions in pain management and chronic care. However, competitive pressures from larger players (Medtronic, Boston Scientific) and product concentration risk present moderate headwinds to sustained growth.

Top Insights

  • Operates in strategic high-growth markets aligned with healthcare trends (opioid reduction, specialized nutrition)
  • Portfolio concentration risk with reliance on key products for significant revenue portion
  • Strong global distribution network spanning 90+ countries with established brand recognition
  • Faces intense competition from larger, better-capitalized medical device manufacturers

Named Competitors

  • Comprehensive Pain & Chronic Care Portfolio — Global leader in medical technology with broad device offerings
  • Minimally Invasive Therapies — Specialized in innovative minimally invasive treatment solutions
  • Infusion Therapy & Pain Management — Major player in infusion systems and pain management
  • Respiratory & Infusion Products — Specialist in respiratory care and infusion systems

Recent Developments

  • (January 2025) Multiple product innovations and expanded market engagement in pain management and interventional therapies
  • (June 2024) Continued clinical evidence generation through participation in professional conferences and hands-on learning initiatives
  • (2023) Net income declined significantly with 2.2% revenue growth to $687.8M, indicating margin pressures

Open the full interactive Avanos Medical, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →